OncoMatch/Clinical Trials/NCT07462650
Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer
Is NCT07462650 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies EB-DUO-CAR-NK-CEA/GCC (IV) for colorectal cancer metastatic.
Treatment: EB-DUO-CAR-NK-CEA/GCC (IV) — This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic colorectal cancer (CRC). Participants are assigned to one of three dual-target arms based on tumor antigen co-expression: (1) CEA+GUCY2C, (2) CEA+HER2, or (3) GUCY2C+HER2. Following dose escalation, the most suitable target pair (based on safety, feasibility, and early efficacy/biomarker signals) will be selected for dose expansion.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Biomarker criteria
Required: CEACAM5 overexpression (central lab threshold)
Tumor antigen co-expression meeting central lab thresholds for one of the following pairs: CEA+GUCY2C, CEA+HER2, or GUCY2C+HER2
Required: GUCY2C overexpression (central lab threshold)
Tumor antigen co-expression meeting central lab thresholds for one of the following pairs: CEA+GUCY2C, CEA+HER2, or GUCY2C+HER2
Required: HER2 (ERBB2) overexpression (central lab threshold)
Tumor antigen co-expression meeting central lab thresholds for one of the following pairs: CEA+HER2, GUCY2C+HER2
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: gene-modified cellular therapy
Exception: within 6 months
Lab requirements
Blood counts
as defined in protocol
Kidney function
as defined in protocol
Liver function
as defined in protocol
Cardiac function
as defined in protocol
Adequate organ function (hematologic, renal, hepatic, and cardiac) as defined in protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07462650 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene-modified cellular therapy disqualifies patients from enrollment.
Does this trial require CEACAM5?
Yes, CEACAM5 overexpression is a required biomarker for enrollment.
Does this trial require GUCY2C?
Yes, GUCY2C overexpression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages